25 results on '"Davis, Cuc"'
Search Results
2. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1
3. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study
4. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
5. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters
6. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen
7. Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up
8. Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study
9. Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma
10. Abstract 365: High throughput screen to evaluate combinations with ibrutinib in various B-cell malignancies
11. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
12. Abstract B18: Quantification of BTK engagement by ibrutinib in peripheral blood mononuclear cells in a phase I clinical study.
13. Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
14. Biomarker Analysis in a Phase Ib Study Combining Ibrutinib with R-CHOP in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)
15. Effects of Ibrutinib on Rituximab and GA-101 Induced Antibody-Dependent Cell Cytotoxicity (ADCC) in Lymphoma Cells in Vitro
16. T-Cell Surface Markers in Human Peripheral Whole Blood Using Flow Cytometry
17. Flow Cytometric Cell-Based Assays: An Overview of General Applications
18. Abstract 2215: Pharmacogenomic investigation of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765): drug sensitivity in diffuse large B-cell lymphoma (DLBCL) within a tumor microenvironment-aligned high-throughput screen.
19. Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry
20. Modulation of CLA, IL-12R, CD40L, and IL-2Rα expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275
21. Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (β1 and β2), IL-2Rα, and CXCR3
22. Co-expression of IL-12 receptors along with CXCR3 and CD25 on activated peripheral blood T lymphocytes
23. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function
24. Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
25. Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (beta1 and beta2), IL-2Ralpha, and CXCR3.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.